Across TCGA pan-cancer cohorts, SINHCAF Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SINHCAF data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SINHCAF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SINHCAF expression acts as an unfavorable survival marker.
HNSC and UCEC are the cancer types where SINHCAF Mutation most reproducibly stratifies survival.